Gastric cancer is one of the most common malignant tumors in the digestive tract, which has the characteristics of high morbidity and mortality. However, gastric cancer is not achieved overnight but is gradually developing through the interaction of many factors. Therefore, actively delaying or blocking the "inflammation-cancer" transformation in gastric mucosa is the key to treatment. Nod-like receptor protein 3(NLRP3) inflammasome is a multi-protein signal complex and one of the important innate immune signal receptors. Inflammation plays an important role in the occurrence and development of gastric cancer, and continuous inflammation mediation will trigger the transformation from inflammation to cancer. Therefore, the significance of NLRP3 inflammasome to gastric mucosa lies in the transformation between inflammation and cancer. Traditional Chinese medicine(TCM) has the functions of multi-components, multi-targets, and few adverse reactions. A large number of studies show that TCM and related monomers have significant effects in treating liver, kidney, and immune diseases through mediating NLRP3 inflammasome, but there is less research on the "inflammation-cancer" transformation in gastric mucosa. By combing the NLRP3-related nuclear factor-κB transcription factor(NF-κB), hypoxia inducible factor-1α(HIF-1α), phosphatidylinositol 3-kinase/protein kinase B(PI3K/Akt), and other signal pathways, this paper clarified their mechanisms in the "inflammation-cancer" transformation in gastric mucosa, delayed the process of "inflammation-cancer" transformation in gastric mucosa through four aspects: energy metabolism, pyroptosis, immune response, and vascular endothelial growth factor, and prevented and treated "inflammation-cancer" transformation in gastric mucosa from three aspects: TCM monomer, TCM compound prescription, and other therapies, so as to provide ideas for the subsequent treatment of "inflammation-cancer" transformation in gastric mucosa with TCM.

Atypical placental site nodules (APSN) are a rare form of trophoblastic disease in pregnancy. There is limited research on APSN, and treatment methods are controversial, with unclear prognosis. This study collected clinical and prognostic data of 5 patients diagnosed with APSN at Xiangya Hospital of Central South University from June 2008 to June 2023, aiming to provide a better understanding of the prognosis of APSN patients and offer scientific evidence for clinical treatment. The average age of the 5 APSN patients was 32.60 years, and all patients underwent dilation and curettage or hysteroscopic surgery or hysteroscopic surgery without hysterectomy. Except for one patient who was lost to follow-up after 30 days, the remaining 4 patients were followed up for 1.36 to 4.61 years. During the follow-up, gynecological ultrasound did not show abnormalities, and serum human chorionic gonadotropin (HCG) tests were negative, with no evidence of malignancy. A search of both English and Chinese databases yielded 8 articles reporting the diagnosis, treatment, and follow-up outcomes of APSN, with 37 cases cumulatively followed up. Among them, 2 (5.41%) cases developed epithelial trophoblastic tumors or placental site trophoblastic tumors during follow-up, but there is insufficient evidence to determine whether these tumors directly originated from APSN or were secondary to APSN. Currently, there is no direct evidence suggesting that APSN has the potential for malignant transformation. Patients with APSN who have completed their childbearing may consider preserving their uterus, but close follow-up is needed to further evaluate the prognosis.

Intravascular large B-cell lymphoma (IVLBCL), a rare subtype of non-Hodgkin lymphoma, is classified as an independent subtype of extranodal diffuse large B-cell lymphoma (DLBCL) in the 2008 World Health Organization (WHO) Classification (Turner et al., 2010). The 5th edition of the World Health Organization (WHO 2022) classification of hematolymphoid tumors retains this subtype (Alaggio et al., 2022). IVLBCL, which is characterized by neoplastic lymphocyte proliferation within the lumen of small blood vessels, tends to invade organs, such as the nervous system, skin, bone marrow (BM), and lung (D'Angelo et al., 2019; Satoh et al., 2019; Vásquez et al., 2019; Fukami et al., 2020).

Primary liver cancer is a common malignant tumor with a high mortality rate. Therefore, early-stage diagnosis and screening are of enormous significance. In recent years, studies have found that bile acids play a key role in the occurrence and development of liver cancer and are expected to become novel diagnostic markers and intervention targets. This article reviews the abnormal changes in bile acid metabolism during the occurrence and development of liver cancer, including the changes in bile acid composition and levels in liver tissue, plasma, feces, and urine, as well as the changes in enzymes related to bile acid metabolism. Furthermore, it expounds the mechanism by which bile acids affect the occurrence of liver cancer, such as participating in multiple signaling pathways to initiate the occurrence and affecting the immune microenvironment, and discusses the potential of bile acids as diagnostic markers for prevention and treatment strategies targeting bile acid metabolism. Bile acids have potential value in the diagnosis and prevention of liver cancer; yet, there are still challenges. In the future, it is necessary to build a large-scale follow-up cohort and biobank, innovate technology for detecting bile acids, and integrate it with multi-omics so as to improve the accuracy of early-stage diagnosis and prevention and treatment of liver cancer.

Non-small cell lung cancer (NSCLC), a leading cause of cancer-related deaths worldwide, remains a significant clinical challenge despite advances in immune checkpoint inhibitors therapy, with drug resistance persisting as a major obstacle. Palmitoylation, a critical post-translational modification (PTM) primarily catalyzed by palmitoyltransferases of the zinc finger DHHC-type (ZDHHC), has recently demonstrated important implications in NSCLC. This review aims to elucidate the mechanisms and clinical potential of ZDHHC-mediated protein palmitoylation in NSCLC progression and immune escape.
.

Peritoneal metastasis is a common form of distant metastasis in patients with colorectal cancer, and it is typically associated with a poor prognosis. The development of peritoneal metastasis involves complex molecular mechanisms and multifactorial regulation of the tumor microenvironment. Due to the presence of the blood-peritoneal barrier, only a small amount of systemic medication reaches the peritoneal cavity, resulting in limited efficacy against peritoneal metastasis. Intraperitoneal administration shows significant therapeutic advantages as it can directly target the tumor microenvironment, maintain high local drug concentrations, and reduce systemic toxicity. Intraperitoneal chemotherapy, especially hyperthermic intraperitoneal chemotherapy, has become a cornerstone therapeutic strategy in the clinical treatment of peritoneal metastasis. When selecting chemotherapy drugs and drug combinations, pharmacokinetic properties, efficacy, and safety must be comprehensively considered to optimize the treatment outcomes. In addition, the unique microenvironment of the peritoneal cavity provides new treatment approaches for biological treatment strategies, including antitoxins, vaccines, immune checkpoint inhibitors, etc. Techniques such as pressurized intraperitoneal aerosol chemotherapy and novel drug delivery systems demonstrate potential for enhanced efficacy, offering promising alternatives to improve patient outcomes. This article will review peritoneal barrier characteristics, intraperitoneal drug transport, intraperitoneal chemotherapy, and intraperitoneal biological therapies, thereby establishing a theoretical framework for precision therapy in colorectal cancer peritoneal metastasis.

Peritoneal metastasis is a common form of metastasis and recurrence in advanced gastric cancer. In recent years, immunotherapy has shown promising applications in the treatment of various malignancies, including gastric cancer. Given the limited efficacy of conventional treatment modalities, such as surgery and chemotherapy, in managing gastric cancer peritoneal metastasis, immunotherapy has garnered increasing attention and recognition among researchers worldwide. However, the application of immunotherapy in gastric cancer peritoneal metastasis still faces significant challenges, including the immunosuppressive tumor microenvironment, drug delivery barriers, and tumor resistance. This review aims to summarize the immunological mechanisms underlying gastric cancer peritoneal metastasis and discuss the latest advances in immunotherapy from both domestic and international studies, with the goal of providing insights for the development of novel immunotherapeutic agents and the optimization of treatment strategies for patients.

Malignant intestinal obstruction is one of the common clinical symptoms of peritoneal metastasis of colorectal cancer, and its pathophysiological mechanism involves various factors such as local invasion and compression of tumors, intestinal adhesions caused by the formation of scattered nodules in the abdominal cavity, inflammatory response in the abdominal cavity, and neuromodulation disorders. Patients with traditional intestinal obstruction are generally treated with surgery, but patients with malignant intestinal obstruction associated with peritoneal metastasis of colorectal cancer can present with multi-level obstruction, complex and diverse symptoms. Combined with multiple metastases in the abdominal cavity and even accompanied by cachexia, malignant intestinal obstruction as a major treatment problem in the field of colorectal surgery is often difficult to be treated by surgery. What's more, it is worth noting that new progress and breakthroughs have been made in the diagnosis and treatment of peritoneal metastasis of colorectal cancer, and the treatment of cancerous intestinal obstruction has also begun to receive extensive attention. Therefore, this article summarizes the clinical features of peritoneal metastasis-related malignant intestinal obstruction in colorectal cancer and looks forward to its treatment challenges.

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an emerging therapeutic modality for peritoneal carcinomatosis. This review aims to evaluate the safety, efficacy, and current clinical application of PIPAC in the treatment of peritoneal metastases originating from gastrointestinal malignancies. This review outlines the technical principles, historical development, procedural steps, commonly used drugs, and administration protocols of PIPAC; analyses the current clinical application status of PIPAC technology; discusses the current challenges and future directions of PIPAC; suggests that PIPAC technology still needs to conduct more high-quality and large-sample clinical trials to further establish the safety and efficacy of PIPAC, optimize its indications and formulate standardized operation specifications. In the future, multi-centre cooperation, multi-disciplinary cooperation, precision medicine strategies and new drug research and development will promote the clinical transformation and standardized application of PIPAC technology.

Systemic chemotherapy currently remains the standard treatment for gastric cancer with peritoneal metastasis (GCPM). However, the plasma-peritoneum barrier significantly limits drug penetration into the peritoneal cavity, resulting in the poor prognosis for GCPM patients. In Singapore, intraperitoneal chemotherapy has been demonstrated as a safe and effective approach for GCPM treatment following the implementation of various modalities including pressurized intraperitoneal aerosol chemotherapy (PIPAC), catheter-based intraperitoneal (IP) chemotherapy and conventional hyperthermic intraperitoneal chemotherapy (HIPEC). This article reviews the evolution of intraperitoneal chemotherapy in Singapore and highlights several important clinical trials. Looking forward, the bidirectional approach combining intraperitoneal and systemic chemotherapy will be further refined through the integration of novel drug combinations, optimization of delivery techniques, and expansion of clinical research.

Despite advances in targeted therapies, the prognosis for patients with peritoneal metastases (PM) from gastric cancer remains poor, due to the "blood-peritoneal barrier," which limits delivery of systemically administered drugs to peritoneal lesions. Intraperitoneal (IP) administration of paclitaxel (PTX) offers pharmacokinetic advantages by enhancing drug retention and infiltration in peritoneal lesions. Normothermic intraperitoneal and systemic chemotherapy (NIPS), developed in Japan two decades ago, combines repeated IP infusion of PTX via an intraperitoneal access port with systemic chemotherapy, and is currently regarded as one of the most effective treatment modalities for managing PM from gastric cancer. This review provides an overview of the theoretical rationale and clinical outcomes associated with this treatment strategy.

Peritoneal metastasis of gastric cancer is a common metastatic form in advanced gastric cancer, and conventional systemic chemotherapy has shown unsatisfactory efficacy. This article systematically examines the clinical value and implementation strategies of normothermic intraperitoneal chemotherapy and systemic therapy (NIPS) in the treatment of gastric cancer peritoneal metastasis. It covers aspects such as the precise selection of treatment candidates, optimization of drug regimens, standardized management of intraperitoneal chemotherapy ports, determination of the appropriate timing for conversion surgery, and postoperative treatment optimization. The aim is to provide scientific guidance for the clinical application of NIPS, promote its standardization, and improve the prognosis for patients with gastric cancer peritoneal metastasis.

Peritoneal metastasis is a key factor in the poor prognosis of advanced gastrointestinal cancer patients. Traditional radiological diagnostic faces challenges such as insufficient sensitivity. Through technologies like radiomics and deep learning, artificial intelligence can deeply analyze the tumor heterogeneity and microenvironment features in medical images, revealing markers of peritoneal metastasis and constructing high-precision predictive models. These technologies have demonstrated advantages in tasks such as predicting peritoneal metastasis, assessing the risk of peritoneal recurrence, and identifying small metastatic foci during surgery. This paper summarizes the representative progress and application prospects of medical imaging artificial intelligence in the diagnosis and treatment of peritoneal metastasis, and discusses potential development directions such as multimodal data fusion and large model. The integration of medical imaging artificial intelligence with clinical practice is expected to advance personalized and precision medicine in the diagnosis and treatment of peritoneal metastasis in gastrointestinal cancers.

Lung cancer is one of the most common and deadliest cancers globally, with its incidence and mortality rates rising each year. Therefore, finding new, safe, and effective alternative therapies poses a significant research challenge in this field. Programmed cell death refers to the process by which cells actively self-destruct in response to specific stimuli, regulated by genetic mechanisms. Modern research indicates that dysregulation of programmed cell death is widespread in the occurrence and progression of lung cancer, allowing cancer cells to evade death while continuing to proliferate and metastasize. Thus, inducing the death of lung cancer cells can be considered a novel therapeutic strategy for treating the disease. In recent years, research on traditional Chinese medicine(TCM) in the field of oncology has gained widespread attention, becoming a focal point. An increasing number of studies have demonstrated that TCM can inhibit the progression of lung cancer and exert anti-cancer effects by inducing apoptosis, necroptosis, pyroptosis, autophagy, and ferroptosis. This paper provided a comprehensive review of the molecular mechanisms of programmed cell death in lung cancer, along with the potential mechanisms and research advancements related to the regulation of these processes by TCM, so as to establish a theoretical foundation and direction for future basic and clinical research on lung cancer.

Extramedullary disease (EMD) is an independent prognostic factor for multiple myeloma (MM). Compared with MM without EMD, MM with EMD has different genetic characteristics, with a higher incidence of high-risk chromosomal abnormalities, more complex genomic profile, and immunophenotypic features related to adhesion molecule and chemokine expression. The mutual regulation between myeloma cells and tumor microenvironment, including changes in immune environment, deposition of extracellular matrix, abnormal expression of adhesion molecules, and autocrine secretion of myeloma cells, is involved in the extramedullary migration of myeloma cells. Various immune-targeted therapies have improved the prognosis of extramedullary MM (EMM). This article reviews the genetic characteristics of EMM, important role of tumor microenvironment, and progress of treatment.

PANoptosis is a type of programmed cell death regulated by the PANoptosome with key features of pyroptosis, apoptosis and/or necroptosis. As the most complex programmed cell death, PANoptosis emphasizes the compensatory role among multiple programmed cell deaths, and can regulate malignant phenotypes such as proliferation, migration, and invasion of tumor cells through multiple signaling pathways, thus affecting malignant tumor progression. It has been found that PANoptosis plays a dual role in tumor progression and treatment. Therefore, it is clinically important to understand the molecular mechanisms by which PANoptosis affects tumorigenesis, development and progression. This paper reviews the molecular mechanisms of apoptosis, pyroptosis and necroptosis, and discusses the activation and regulation mechanisms of PANoptosis and PANoptosome as well as the research progress on the role of PANoptosis in tumors, aiming to provide new ideas for cancer treatment and prognostic assessment.

Malignant proliferating liver cancer cells possess the ability to detect and respond to various body signals, thereby facilitating tumor growth, invasion, and metastasis. One crucial mechanism through which hepatocellular carcinoma (HCC) cells interpret these signals is crosstalk. Within liver cancer tissues, cancer cells engage in communication with hepatic stellate cells (HSCs), tumor-associated macrophages (TAMs), and immune cells. This interaction plays a pivotal role in regulating the proliferation, invasion, and metastasis of HCC cells. Crosstalk occurs in multiple ways, each characterized by distinct functions. Its molecular mechanisms primarily involve regulating immune cell functions through the expression of specific receptors, such as CD24 and CD47, modulating cell functions by secreting cytokines like transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), and mediating cell growth and proliferation by activating pathways such as Wnt/β-catenin and Hedgehog. A comprehensive understanding of the mechanisms and interactions within crosstalk is essential for unraveling the pathogenesis of HCC. It also opens up new avenues for the development of innovative therapeutic strategies. This article reviews the relationship between crosstalk and the progression of HCC, offering insights and inspiration for future research.

In the past decade, great progress has been made in the field of gynecological pathology in China, especially in the field of pathology of female reproductive tract tumors. Gynecological pathologists have not only made a lot of research work in pathological diagnosis and its clinical application, but also issued several expert consensus and guidelines, and edited and translated a number of monographs. All above efforts have made a positive contribution to improving the level of gynecological pathology nationwide.